ATRS - Earnings announcements

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which exclu

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The conference ID number is 9589807. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antares

Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "Our third quarter financial and operating results are illustrative of the strong execution that we continue to deliv

EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens. Antares will host a conference call on Thursday, November 4, 2021 at 8:30am ET to discuss the results. The dial-in numbers are (800) 353-6461 for domestic callers and (334) 323-0501 for international callers. The conference ID number is 2794616. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antarespharma.co

Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today reported financial and operating results for the second quarter ended June 30, 2021 with record revenue of $45.0 million and net income of $4.4 million, or $0.03 per basic and diluted earnings per share. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "We believe our strong second quarter performance highlights the growth opportunities that prevail across our diversified bu

EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens. Antares will host a conference call on Thursday, August 5, 2021 at 8:30am ET to discuss the results. The dial-in numbers are (800) 367-2403 for domestic callers and (334) 777-6978 for international callers. The conference ID number is 3020992. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antarespharma.com.